Current Neuro-Oncology

Volume 28 Number 22
10 August 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 22, 10 August

Kim K, Song SW, Jeon Y, Choi S, Choi J, Jun S, Park JH, Lee SJ, Han N, Dho YS, Shin SH, Yoo H, Wang KC, Gwak HS.
Phase I trial of IL13Rα2-targeted CAR-T cell therapy for recurrent malignant glioma: clinical results and pharmacokinetics.
Clin Cancer Res. 2026 Aug 4. doi: 10.1158/1078-0432.CCR-26-0645. PMID: 42550847. Trial registration ID: NCT05540873. ˍ

Lissoni P, Monzon A, Marroccoli S, Di Fede G, Sassola A, Messina G, Simoes-E-Silva AC, Kuznetsova IV, Burchakov DI, Kirillova MY, Cardinali DP.
Neuroimmune treatment of advanced solid tumors: 3-year survival after angiotensin 1-7, pineal indoles, and cannabinoids.
Neoplasma. 2026 Aug 4:260610N190. doi: 10.4149/neo_2026_260610N190. PMID: 42549589. ˍ

Výmolová B, Pfeiferová L, Smetana TK, Výmola P, Ternerová N, Zubaľ M, Kolář M, Šáchová J, Gyönyörová S, Balážiová E, Houdová Megová M, Červenka J, Kupcová Skalníková H, Španko M, Smetana K Jr, Lacina L, Netuka D, Tomáš R, Bušek P, Šedo A.
Brain metastasis-associated fibroblasts shape the tumour microenvironment to enhance cancer cell invasion.
Brain Pathol. 2026 Aug 4:e70129. doi: 10.1111/bpa.70129. PMID: 42551489. ˍ

Destro A, Panebianco F, Durães C, Quagliata L, Rudini N, Bianchi G, Salvati A, Russo CL, Piombo C, Uccella S, Terracciano L. Transforming routine solid tumor profiling with automated next-generation sequencing: experience from a reference general hospital.
Virchows Arch. 2026 Aug 5. doi: 10.1007/s00428-026-04658-0. PMID: 42554859˰ ˍ

Gatellier L, Nakata K.
Age-standardized mortality-to-incidence ratio for brain and central nervous system tumors in the world.
Jpn J Clin Oncol. 2026 Aug 5;56(8):1027-1028. doi: 10.1093/jjco/hyag120. PMID: 42555108˰ ˍ

Li L, Zhang J, Wu W.
Second primary malignancies among childhood medulloblastoma survivors: a population-based competing risk analysis.
Childs Nerv Syst. 2026 Aug 6;42(1):326. doi: 10.1007/s00381-026-07427-1. PMID: 42562951˰ ˍ

Oh HC, Choi RJ, Jo SY, Yeo E, Jo E, Shim JK, Kim K, Kim SJ, Cho HJ, Kim HJ, Lee JH, Yoon SJ, Kim RN, Won J, Park J, Kang S, Yoo J, Moon JH, Roh TH, Kim EH, Kim SH, Chang JH, Kim AH, Kim HS, Lee JH, Kim H, Kim S, Kang SG.
Putative glioblastoma origin-like cells in the subventricular zone: isolation and characterization.
Exp Mol Med. 2026 Aug 6. doi: 10.1038/s12276-026-01801-4. PMID: 42562888. ˍ

Zhang Y, Chi X, Feng R, Xian N, Huang N, Sun S, Zhao X, Zhang P, Liu K, Ma Y, Zhang Y, Zhang K, Wang S, Chen X, Zhang J, Huang W, Huang B, Su TT, Yeung J, He J, Chen L, Ji N, Huang G.
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial.
Nat Med. 2026 Aug 6. doi: 10.1038/s41591-026-04557-6. PMID: 42562965. Trial registration ID: NCT05241392˰ ˍ

Cao X, Guo H, Wang K, Wu Q, Wang X, Shao J.
The gut-immune-brain axis in CNS tumors: Causal roles of microbiota and inflammatory proteins unveiled by Mendelian randomization and single-cell transcriptomics.
Medicine (Baltimore). 2026 Aug 7;105(32):e50109. doi: 10.1097/MD.0000000000050109. PMID: 42566596. ˍ

Hounchonou HF, Polemikos M, Pirayesh A, Bajgora G, Al-Afif S, Hartmann C, Krauss JK.
Molecularly diagnosed glioblastoma: clinical presentation and outcomes.
J Neurooncol. 2026 Aug 7;179(1):35. doi: 10.1007/s11060-026-05752-8. PMID: 42567974. ˍ

de Jong AM, van der Boog ATJ, Wester G, Eekers DBP, Budiharto TCG, Rozema T, Lagerwaard FJ, Bruynzeel AME, de Groot C, van der Meulen M, Cialdella F, Dankbaar JW, Hendrikse J, Kleynen KE, Claes A, Philippens MEP, Smid EJ, de Vos FYFL, van Rossum PSN, Robe PA, David S, Snijders TJ, Verhoeff JJC.
Ultra-hypofractionated versus conventional chemoradiation for newly diagnosed glioblastoma: Survival and toxicity results of a multicenter randomized trial.
Radiother Oncol. 2026 Aug 8;223:111726. doi: 10.1016/j.radonc.2026.111726. PMID: 42570798. Trial registration ID: NL72953.041.20. ˍ